Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Rituximab Biosimilar PF-05280586

Known as: PF-05280586 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Biosimilars are highly similar to the licensed biologic (“reference product”), with no clinically meaningful differences in… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?
2018
2018
Objective This extension study provided continued treatment to subjects with active rheumatoid arthritis who had participated for… Expand
  • figure 1
  • table 1
  • table 3
  • table 4
  • figure 2
Is this relevant?
2018
2018
PURPOSE With the introduction of biosimilars of anticancer monoclonal antibodies (mAbs) in oncology, physicians are potentially… Expand
Is this relevant?
Review
2018
Review
2018
Background: This comparative 52 week clinical study (NCT02213263) evaluated the efficacy, safety, immunogenicity… Expand
Is this relevant?
2016
2016
Aims Pharmacokinetic (PK) similarity was assessed among PF‐05280586 (a proposed biosimilar) vs. rituximab sourced from the… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
2016
2016
Aims To evaluate potential differences between PF‐05280586 and rituximab sourced from the European Union (rituximab‐EU) and USA… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2015
2015
Background Rituximab is a genetically engineered chimeric murine/human monoclonal immunoglobulin (Ig) G1 κ-antibody directed… Expand
Is this relevant?
2014
2014
Comparative nonclinical studies were conducted with the proposed biosimilar PF-05280586 and rituximab-EU (MabThera®). In side-by… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
Is this relevant?
2014
2014
Background PF-05280586, a proposed biosimilar to rituximab, has the same primary amino acid sequence as rituximab with similar… Expand
Is this relevant?
2013
2013
Background Rituximab is a genetically-engineered chimeric mouse/human IgG1 cytolytic monoclonal antibody (mAb) targeting the CD20… Expand
Is this relevant?